Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.…
Sera: 3 Key Takeaways for Long-Term Investors
Sera Prognostics (NASDAQ: SERA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 71 employees.
The shares were at 1.810 USD on 20 November 2026, down 33.0% over 52 weeks. Its 52-week range is 1.560 USD to 3.850 USD: the price is 53.0% below the high and 16.0% above the low.
Its market capitalisation is 71.98M USD.
Sera Prognostics reports return on equity of -42.3% and revenue up 162.5% year over year.
It holds more cash than debt, a net cash position of 40.82M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 5.000 USD is 176.2% above the current price. The next earnings report is expected on 17 March 2027.